Over the past decade, researchers have made great strides in the development and administration of cancer immunotherapies, which use the body’s own immune system to treat disease. However, the therapies don’t work for every person or with every type of cancer, and gaps in our understanding of exactly how the body mounts an anti-cancer immune response has slowed progress toward making them universally effective.
In a new study, researchers at the University of Chicago Medicine Comprehensive Cancer Center and the University of Amsterdam have brought insight into one crucial step in the anti-cancer immune response process: T cell priming.
Previous studies implied that a single mechanism—antigen cross presentation—is responsible for priming T cells, the immune system’s disease fight...
Read More
Recent Comments